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Abstract 
ARR is an antibiotic resistance protein found in Mycobacterium smegmatis with 
several homologues in other species and genera. ARR inactivates rifampicin through 
the transfer of an ADP-ribose group from NAD+ to C23 of rifampicin. This work 
aimed to characterize ARR both biochemically and functionally. ARR was 
heterologously expressed and purified to a homogenous level. Using far-UV circular 
dichroism it was found that ARR has a mixed alpha helical and beta sheet secondary 
structure. It was also shown that ARR retains a high proportion of this structure after 
heating from 10 °C to 85 °C. Fluorescence spectroscopy showed the two tryptophans 
(W59 and W107) in ARR to be solvent exposed. These findings are congruous with 
the crystal structure of ARR. Study of cell wall morphology revealed that expression 
of ARR led to increased cell length in E. coli and branching in M. smegmatis. We 
suggest other possible targets for ARR in M. smegmatis based on the bld pathway in 
S. coelicolor which involves an ADP-ribosyltransfer reaction leading to changes in 
cell wall morphology. These targets are extracellular binding protein, sugar binding 
lipoprotein and D-xylose binding periplasmic protein. These targets suggest a role for 
ARR in nutrient sensing and stress response. 
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ADP Adenosine diphosphate 
AIDS Acquired Immune Deficiency Syndrome 
ART Mono ADP-ribosyltransferase 
ATP Adenosine triphosphate 
Bp Base pair 
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mm Millimetre 
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1 Introduction 
1.1 Mycobacteria 
Mycobacteria are acid fast Gram positive filamentous bacteria and are the only 
member of the family Mycobacteriaceae within the order Actinomycetes (NCBI). The 
genus Mycobacterium is made up of more than 30 species and numerous subspecies 
which are closely related to Nocardia and Corynebacterium. Like these organisms the 
mycobacterial genome has a high G-C content. The most distinguishable feature of 
mycobacteria is their ability to produce large amounts of long chain fatty acids known 
as mycolic acids and incorporate them into their cell walls. The genus can be divided 
into the fast growing mycobacteria (e.g. M. smegmatis) and the slow growing 
mycobacteria such as M. tuberculosis (Springer et al., 1996). 
 
M. smegmatis was first isolated from human smegma (genital secretion). Although M. 
smegmatis is considered to generally be non-pathogenic it has been implicated in 
several human infections especially those around wounds after trauma (Newton et al., 
1993). Geographically, M. smegmatis is widely distributed with isolates reported in 
the United States of America, Canada, Australia, Switzerland and Russia (Brown et 
al., 1999; Pennekamp et al., 1997; Wallace et al., 1988). M. smegmatis is an ideal 
mycobacterial model as it is non-pathogenic and fast growing (Snapper et al., 1990); 
while some pathogenic species of Mycobacterium take six to seven weeks to culture, 
M. smegmatis can be grown in four days. 
 
1.1.1 Mycobacterial cell walls 
Mycobacterial cell walls are made up of three types of polymers that are covalently 
linked. These polymers are peptidoglycan, arabinogalactan and mycolic acids (see 
Figure 1.1). The peptidoglycan and arabinogalactan form what is known as the AG 
complex which is linked by phosphodiester bonding to the mycolic acids (Petit et al., 
1969). Nearly 60% of the mycobacterial cell wall is made up of lipids (Wang et al., 
2000); this is highly unusual in bacterial cells. Mycolic acids are unique to 
9 
 
Mycobacteria and closely related genera including Nocardia, Rhodococcus and 
Corynebacterium (Frieden, 1993). 
 
Mycolic acids are α-alkyl-β-hydroxy fatty acids which are long and complex (See 
Figure 1.2). Mycolic acids have a very low fluidity and make up the inner leaflet of 
the lipid bilayer of mycobacterial cell walls. The presence of mycolic acids may 
explain the extremely low permeability of mycobacterial cell walls (Wang et al., 
2000). This low permeability partially accounts for the low level of antibiotic 
susceptibility in many mycobacterial species. Mycolic acids also help in disease 
persistence in mycobacterial infections by shielding the bacteria from stress during 
infection (Barry and Mduli, 1996). 
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Figure 1.1 Schematic representation of the proposed structure of M. tuberculosis cell 
wall (Abdallah et al., 2007). Note the mycolic acid layer which makes the membrane 
thick and hardy. Typically, non-pathogenic mycobacteria do not have a capsule. 
 
 
 
 
 
 
 
 
Figure 1.2 Generalized mycolic acid structure (Asselineau and Lederer, 1950). 
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1.1.2 Pathogenicity 
By far the best known pathogenic mycobacteria are M. tuberculosis and M. leprae, 
the causative agent of leprosy. Both are slow growing mycobacteria.  In addition to 
these well-known pathogens there are a number of other slow growing mycobacterial 
species which cause human infections (Brosch et al., 2001). M. bovis infects a 
number of mammalian hosts including humans. M. ulcerans is the cause of an 
epidemic of cutaneous infections in West Africa and atypical mycobacterial 
infections such as the Mycobacteria avium intracellulare complex are increasingly 
found to be associated with HIV (Shafran, 1996). Of the fast growing mycobacterial 
species, the M. fortuitum group is most commonly associated with human disease. 
 
1.1.3 Mycobacterium tuberculosis 
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB). In 2003 there 
were estimated to be nine million new TB infections, with the total number of 
infected people expected to rise to one billion by the year 2020 (WHO, 2006). TB 
causes more deaths worldwide than any other curable infectious disease (WHO 
Report, 2004). TB rarely affects young children and affects more men than women 
with incidence rates highest in young adults (Dye et al., 2007).  
 
In 2003, 31% of worldwide TB deaths occurred in Africa although Africa has only 
11% of the world’s population (See Figure 1.3).Although the rate of TB infections 
fell in all other regions between 1997 and 2006, the rate of infections continued to 
increase in Sub-Saharan Africa (Dye et al., 2009). In Sub-Saharan Africa, 75% of TB 
deaths are HIV-related (WHO Report, 2005). In Africa, TB is the leading cause of 
death in HIV-infected individuals. Rates of recurring TB infection in patients with a 
previous history of HIV-related TB is frequent (Churchyard, 2003; Seyler et al., 
2005). Multidrug resistant TB is defined as a strain which is resistant to at least 
12 
 
rifampicin and isoniazid and is becoming increasingly common in Africa. Treatment 
of multidrug resistant TB is expensive, often toxic and is generally unavailable in 
Africa (Dean et al., 2002). Multidrug resistant TB has a high fatality rate and low 
treatment success (Frieden, 2002). 
 
1.2 Rifampicin 
Rifampicin (known as rifampin in the United States) was first produced by Dow- 
Lepetit Laboratories in Milan, Italy in the mid 1960s (Sensi, 1983). Rifampicin is a 
semi-synthetic derivative of rifamycin B, which was isolated as a natural 
fermentation product of Nocardia mediterranei. N. mediterranei was initially placed 
in the genus Streptomyces but was later reclassified (Margalith and Pagani, 1961). 
Although five rifamycins were initially isolated from N. mediterranei designated 
rifamycin A through E, only rifamycin B was found to be stable (Sensi et al., 1960). 
 
Although rifamycin B was found to have no antibacterial activity it became 
‘activated’ in an oxygenated aqueous solution (Sensi et al., 1960). The mechanism of 
this ‘activation’ was found to be caused by the spontaneous conversion of rifamycin 
B into rifamycin O, which is then hydrolysed into rifamycin S by losing a single 
molecule of glycolic acid. Once rifamycin S is mildly reduced, rifamycin S yields 
rifamycin SV (Sensi et al., 1960).  
 
 
 
 
 
 
 
 
 
 
13 
 
 
 
 
 
 
 
 
 
Figure 1.3 Disproportionate burden of HIV, HIV-related tuberculosis, and M. 
tuberculosis co-infections in Africa, for 2000. Every person represents 5% of the 
global total, with African people shown in red and the rest of the world in blue 
(Taken from Corbett et al., 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Chemical structure of rifampicin and its precursor rifamycin B (Watanabe 
et al., 2003). 
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Rifamycin SV was found to be highly active against bacteria, especially Gram 
positives such as Mycobacterium tuberculosis. However it was not suitable for oral 
administration as it is not easily absorbed by the gastrointestinal tract and is quickly 
metabolised by liver enzymes leading to undetectable levels in the blood stream 
(Sensi, 1983). During a study which produced several hundred synthetic variations of                      
Rifamycin SV, rifampicin was discovered.. Rifampicin is 3- formylrifamycin SV 
with N-amino-N´-methylpiperazine (see Figure 1.4). Rifampicin was found to be 
highly antimicrobial, easily absorbed and not toxic in the doses required for 
treatment. In 1968, rifampicin was introduced into TB therapy in Italy and was 
approved by the United States Food and Drug Administration (FDA) in 1971 (Sensi, 
1983). 
1.2.1 Mode of action 
Rifampicin inhibits prokaryotic transcription through tight binding to RNA 
polymerase (see Figure 1.5). This was first shown by Hartman in 1967. There are five 
stages of transcription, namely; binding of polymerase to DNA; binding of the first 
nucleoside triphosphate to the DNA-polymerase complex; chain initiation through the 
formation of the first phosphodiester bond; chain elongation by the assembly of more 
nucleotides; chain termination by release of the complete polyribonucleotide. 
Rifampicin aborts chain elongation by preventing the formation of the second 
phosphodiester bond once chain initiation has taken place (Johnson and McClure, 
1976). 
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Figure 1.5 Mechanism of transcriptional inhibition by rifampicin. The RNA itself 
and the rest of the nucleic acids have not been depicted for reasons of clarity. Mg2+ is 
represented by the magenta sphere. The ribonucleotides are labeled with respect to 
the initiation site. The incoming nucleotide substrate at the -1 position is shown in 
green and the -1 and -2 positions that can be accommodated in the presence of 
rifampicin are depicted in yellow. The RNA further upstream (-3 to -8) that cannot be 
accommodated in the presence of rifampicin is coloured pink. The DNA template 
strand is grey. Rifampicin is shown positioned in its binding site on the β subunit. 
The carbon atoms are coloured in orange while the oxygen and nitrogen atoms are 
coloured in red and blue respectively (Nicholls et al., 1991). The rifampicin is 
partially transparent, illustrating the RNA nucleotides (at -3 to -5) that sterically 
clash.  
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RNA polymerase consists of five subunits α(2)ββ′σ. Rifampicin binds to the β subunit 
of prokaryotic RNA polymerase (Mindlin et al., 1972). This binding is lipophilic with 
the lipophilic ansa chain of rifampicin extending furthest into the polymerase 
(Stender and Scheit, 1977). By binding in this manner, rifampicin prevents chain 
elongation of the di-ribonucleotide formed at the chain intiation stage. 
 
1.2.2 Mechanisms of resistance 
The most common mechanism of rifampicin resistance is the mutation of nucleotides 
within the rpoB gene which encodes the β-subunit of RNA polymerase (Jin and 
Gross, 1988; Telenti et al., 1993; Williams et al., 1994). The mutations prevent the 
binding of rifampicin to the RNA polymerase. rpoB mutations conferring rifampicin 
resistance are located within a 225 bp region of the gene (Jin and Gross, 1998). These 
mutations usually affect amino acids in regions 502-532; 560-572 and 687 (Aubry-
Damon et al., 1998). 
 
Studies of M. smegmatis, M. intracellular and M. avium have indicated that 
rifampicin resistance in these organisms occurs by mechanisms other than rpoB 
mutations (Guerro et al., 1994; Hetherington et al., 1995). It has been established that 
there were four types of rifampicin resistance which inactivate the drug: glucosylation 
(Yazawa et al., 1994); decomposition (Dabbs et al., 1987); phosphorylation (Yazawa 
et al., 1994); ribosylation (Dabbs et al., 1995; Quan et al., 1997). 
 
Inactivation of rifampicin by glusosylation involves the substitution of the hydroxyl 
group of C23 in rifampicin with a β-D-glucose (Yazawa et al., 1994). This form of 
inactivation is prominent in the Nocardia. Another mechanism used by Nocardia as 
well as Rhodococcus, is that of phosphorylation. During this process a phosphate 
group is added to the ansa bridge of rifampicin at C21 (Yazawa et al., 1994). 
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Decomposition of rifampicin is widespread through a number of bacterial genera 
including Nocardia, Mycobacteria and Rhodococcus (Dabbs et al., 1987; Andersen et 
al., 1997). Ribosylation is a relatively newly discovered mechanism of antibiotic 
inactivation and appears to be limited to rifampicin inactivation (Dabbs et al., 1995; 
Quan et al., 1997, Baysarowich et al., 2008). 
 
1.2.3 Rifampicin in the treatment of infections 
Rifampicin is far more effective against Gram positive organisms because there is 
ineffective penetration of Gram negative cell walls by rifampicin (Wehrli, 1980). Its 
efficacy against Gram positives resulted in its identification as a potential TB 
treatment early on in its development (Sensi, 1983). Today, rifampicin is recognized 
as the primary TB treatment along with isoniazid.  
 
In addition to treatment of TB, rifampicin has been successfully used in the treatment 
of numerous infections including urinary tract infections, bone infections, 
endocarditis, foreign-body related infections, respiratory tract infections, bacterial 
meningitis, as well as skin and soft-tissue infections (Bliziotis et al., 2007). 
Rifampicin is also being increasingly used in the treatment of drug resistant 
Staphylococcus aureus (Ellis et al., 2009). 
 
1.3 ADP-ribosyl transferases  
ADP-ribosylation involves the transfer of an ADP-ribose group from NAD+ to a 
substrate with the loss of nicotinamide. Collier was the first to elucidate the 
mechanism of an ADP-ribosylation reaction when studying the effect of diphtheria 
toxin on elongation factor 2 (Collier, 1967). Many well-studied ADP-ribosyl 
transferases are bacterial toxins. These include cholera toxin, diphtheria toxin, 
pertussis and Pseudomonas aeruginosa exotoxins A and S. All bacterial toxins which 
act through ADP-ribosylation act on one G-protein specific to that toxin (Shall, 
1995). Some bacterial ADP-ribosyl transferase toxins are encoded by bacteriophages 
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which infect the bacterium (Uchida and Pappenheimer, 1971). Reversible ADP-
ribosylation regulates nitrogenase in photosynthetic bacteria (Ludden, 1994). The 
human genome contains some ADP-ribosyl transferase genes of bacterial origin 
(Lander et al., 2001). 
 
In eukaryotes, ADP-ribosyl transferases are divided into mono ADP-ribosyl 
transferases (ARTs) and poly ADP-ribose polymerases (PARPs). The PARP 
superfamily consists of eighteen classes of proteins displaying a conserved catalytic 
domain (Amé et al., 2004). The most extensively studied PARPs are nuclear-
localised proteins which poly ADP-ribosylate proteins post-translationally. PARP-1 
and PARP-2 are involved in the single-strand break repair and base excision repair 
pathways. PARP1 has also been implicated in the apoptotic pathway and has thus 
been identified as a possible cancer inhibitor. PARP-3 has been shown to interact 
with PARP-1 in the centrosome. For review articles (see Amé et al. (2004) and 
Bürkle (2005). 
 
The ARTs are a relatively small gene family (Glowacki et al., 2002). The majority of 
ARTs are ectoenzymes which act on extracellular substrates (Corda and Di Girolamo, 
2003). Intracellular ARTs have been implicated in cell cycle regulatory pathways 
through binding to G-protein β-subunit and preventing modulation of effectors such 
as phosphoinositide 3-kinase (Lupi et al., 2000). For a full list of mono ADP-
ribosyltransferases see Table 1. 
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Table 1 Mono ADP-ribosyl transferases, their sources and substates (Corda and Di 
Girolamo, 2003). 
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The above mentioned ADP-ribosyltransferases all act on proteins, share a similar 
global fold and use the same catalytic mechanism (Yates et al., 2006; Hollburn et al., 
2006). The ADP-ribose group is added to a nitrogen atom on a susceptible amino 
acid, often arginine. 
 
1.4 ADP-ribosylation in Streptomyces coelicolor 
In the filamentous actinomycetes, a novel developmental cycle leads to the formation 
of an aerial mycelium at the beginning of differentiation (Kelemen and Buttner, 
1998). In S. coelicolor, vegetative substrate hyphae are formed at spore germination. 
These hyphae rise to aerial hyphae which further differentiate into chains of 
exospores (Elliot et al., 1998). The formation of the aerial hyphae coincides with the 
production of secondary metabolites including antibiotics. The production of aerial 
hyphae is known as morphological differentiation while the production of secondary 
metabolites is known as physiological differentiation. 
 
Both physiological and morphological differentiation in S. coelicolor are under the 
control of the bld genes, known as such because colonies of bld mutants have a shiny 
“bald” appearance because they lack aerial hyphae (Kelemen and Butler, 1998). 
There are 10 bld genes: bldJ (formerly bld216), bldA, bldB, bldC, bldD, bldF, bldG, 
bldH, bldI and bldK (Merrick, 1976; Puglia and Cappelletti, 1984; Champness, 1988; 
Harasym et al.,1990; Wiley et al.,1993). 
 
ADP-ribosylation is a key factor in the bld pathway (Shima et al.,1996; Sugawara et 
al.,2002). A regulatory locus designated brgA was found to play an essential role 
early on in the differentiation process by modulating the activity of proteins through 
ADP-ribosylation (Shima et al.,1996). In addition, bldB, bldC and bldH mutants 
failed to ADP-ribosylate a number of proteins which were ADP-ribosylated in parent 
wild type strains. BrgA leads to the ADP-ribosylation of at least four proteins in S. 
coelicolor (Sugawara et al.,2002). These proteins are BldKB, MalE and two 
21 
 
periplasmic proteins. It is not clear if brgA encodes an ART or encodes a factor which 
controls transcription of an ART encoding gene. 
 
BldKB is a member of the bldK cluster of genes which encode the components of an 
oligopeptide importer-exporter which is a member of the ATP-binding cassette 
(ABC) membrane spanning transporter family (Nodwell et al., 1996). BldK is the 
transporter which is responsible for importing a bldJ dependent extracellular signal 
which initiates the bld signaling cascade. BldKB is an extracellular subunit of BldK. 
MalE is involved in maltose utilization (Driessen et al., 2000) and the two 
periplasmic proteins are part of high affinity active transport (van Wezel et al., 1977). 
 
These target proteins are all on the membrane and are involved in nutrient transport. 
They appear to be ADP-ribosylated on the thiol group of cysteine as shown by the 
susceptibility of the linkage to mercuric chloride treatment. Sugawara et al identified 
specific cysteine residues within these proteins as putative locations of ADP-
ribosylation (Sugawara et al., 2002). These cysteine residues are all situated in the N-
terminal region of the proteins and there is a common amino acid sequence flanking 
them: Leu (or Ala) – Thr (or Ala) – Ala –Cys – Gly. This sequence is a known 
lipoprotein signal sequence and is the site at which lipoprotein modification occurs 
which is essential for the export of lipoproteins as well as their anchoring to the 
membrane (Wu et al., 1996). 
 
If these cysteine residues are the site of ADP- ribosylation, then these proteins would 
no longer be recognized by enzymes which form N-acyl-diacylglycerylcysteine and 
would not be exported to the membrane and would not be able to act in transport of 
nutrients (Sugawara et al., 2002). 
 
1.5 ARR 
The only known naturally occurring ADP-ribosylation of a small non-proteinaceous 
target occurs in M. smegmatis in which rifampicin is ADP-ribosylated by the enzyme 
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ARR (Dabbs et al., 1995; Quan et al., 1997; Quan et al., 1999). This ADP-
ribosylation leads to the inactivation of the antibiotic. The ARR (name derived from 
ADP-ribosylates rifampicin) gene was identified in a genomic library of DNA of M. 
smegmatis DSM 43756 (Quan et al., 1999).  
 
The gene is 429 bp in length and begins with a GTG start codon (Quan et al., 1997). 
Although AUG is accepted as a universal start codon, Mycobacteria frequently use 
GTG as a start codon. In keeping with the predicted size of the translated product of 
this gene the ARR protein is small ≈16kDa ,143 amino acids (see Sequence 1). The 
gene showed no sequence similarity to known ADP-ribosyl transferases. A putative 
upstream regulatory element has high sequence similarity to an upstream region of 
another rifampicin inactivation gene from Rhodococcus equi iri, suggesting a 
common regulatory mechanism between the two genes (Quan et al., 1997). 
 
VVARNPPKPF  EVHESGAYLH  GTKADLKVGD  RLVPGRESNFE  
AGRIMKHVYI  TQTLDAAVWG  AELAVGEGRG  RIYIVEPEGH  
IHDDPNVTDK  KLPGNPTRSY  RTREPVRIVG  ELTDWEGHSP  
EQIAAMREGL           EDLRRKGLAV           IYD 
Sequence 1: ARR amino acid sequence. 
 
1.5.1 Structure 
In 2008, the crystal structure of ARR was determined by Baysarowich et al. ARR is 
made up of a single domain containing seven β-strands (arranged in two antiparallel 
β-sheets) and two α-helices (Baysarowich et al., 2008). The two β-sheets (β1-4-7-2 
and β3-6-5) are arranged almost perpendicularly to one another. The two α-helices 
form the deep cleft into which rifampicin binds. Once rifampicin has bound, an 
extended loop region containing β5 and β6 closes over the rifampicin forming a lid 
(see Figure 1.7). 
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It is significant that although rifampicin is quite deeply buried within ARR there are 
no ionic or covalent bonds formed between rifampicin and any of the amino acid side 
chains of ARR (Baysarowich et al., 2008). Apart from two hydrogen bonds, formed 
with N86 and K91, the interaction is entirely hydrophobic. This allows a high degree 
of plasticity in this interaction suggesting that ARR may be able to act on 
hydrophobic substrates other than rifampicin. 
 
In 2008 Gianniosis et al found that the single amino acid substitution P5T caused a 
significant change in charge distribution (Gianniosis et al., 2008). Their work was 
carried out before publication of the ARR crystal structure later the same year; 
however, the elucidation of the structure shed no light on possible reasons for this 
change as P5 is not represented in the structure, as there is no electron density beyond 
residue six (see figure 1.6) This mutation did not affect the minimum inhibitory 
concentration of rifampicin in mutant cells in comparison to cells expressing the wild 
type protein, indicating that it does not affect activity. There was also no change to 
the predicted hydrodynamic volume between mutant and wild type protein, again 
suggesting that the mutation does not lead to global conformational changes, although 
it is notable that the estimated hydrodynamic volume obtained by dielectric 
spectroscopy is twice that of the value estimated by the crystal structure.  
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Figure 1.6: Electron density map of ARR viewed with ARR co-ordinate file viewed 
in Coot (Emsley and Cowtan, 2004). Electron density is shown in blue. Proline six is 
marked. There is no clear electron density beyond this point. PDB co-ordinate 2HW2. 
 
Proline 6 
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Figure 1.7 Ribbon diagram representing the crystal structure of ARR bound to 
rifampicin (Taken from Baysarowich et al., 2008).  Rifampicin is shown in bright 
yellow, β-strands in red and α-helices in blue. Helices and strands are numbered. The 
carboxy and amino termini are marked by C and N respectively. B is a 180º rotation 
of A about the horizontal axis. 
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1.5.2 Mechanism 
ARR adds an ADP-ribose group onto the oxygen atom at C23 of rifampicin. The 
preferred source of ADP-ribose is NAD+ (Baysarowich et al. 2008). ADP-ribosylated 
rifampicin has also been termed RIP-TA (Quan et al., 1999) The structure of RIP-TA 
(MW 1.363 kDa) has been determined by 1H and 13C nuclear magnetic resonance 
(NMR) analyses; 1H-1H correlated spectroscopy, pulsed-field gradient heteronuclear 
multiquantum coherence, and pulsed-field gradient heteronuclear multiple-bond 
correlation and its chemical formula has been determined as C58H79N9O25P2 (see 
Figure 1.8). 
 
In the predicted molecular mechanism of ARR-mediated ADP-ribosylation of 
rifampicin (using ARR’s structure and known mechanisms of other ADP-
ribosyltransferases), Asp84 stabilises the development of a oxocarbenium ion 
allowing a transition-state which allows attack of C23 of rifampicin by C1 of the 
ribose (see Figure 1.9). Dabbs and Quan suggested that ARR may use FAD+ as a 
source of ADP-ribose, because the reaction is inhibited by light (Dabbs and Quan, 
2000) 
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Figure 1.8 ADP-ribosylated rifampicin (taken from Quan et al., 1999). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADP-Ribose 
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Figure 1.9 Schematic representation of ARR catalysed ADP-ribosylation of 
rifampicin (taken from Baysarowich et al., 2008). Transition state indicated by *. 
 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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1.5.3 Enzyme activity 
ARR can ADP-ribosylate a wide variety of rifamycins with diverse naphthyl 
substituents (Baysarowich et al., 2008). These rifamycins are all of clinical 
importance including rifampicin (TB treatment), rifabutin (Mycobacterium avium 
complex treatment) and rifaximin (prophylactic treatment of traveller’s diarrhoea). 
 
Steady-state kinetic parameters have been determined for ARR. Km values for 
binding of rifampicin and NAD+ are in the millimolar range (Baysarowich et al., 
2008). kcat/Km values which indicate an enzyme’s ability to catalyse a reaction at a 
low substrate concentration are 2.00 x 103 s-1·M-1 for rifampicin and 1.54 x 104 s-1·M-1 
for NAD+. 
 
1.5.4 Homology 
1.5.4.1 Sequence  
ARR derived from M. smegmatis shows no sequence identity with other known mono 
or poly ADP-ribosyltransferases. However, another form of the ARR gene designated 
ARR-2 shows a 55% sequence identity and is present as a mobile genetic element in 
numerous bacteria (Baysarowich et al., 2008). ARR-2 integrons or transposons are 
most notably found in several Gram-positive pathogenic bacteria including 
Pseudomonas areuginosa (Tribuddharat and Fennewald, 1999), Escherichia coli 
(Naas et al.,2001), Klebsiella pneumoniae (Arlet et al., 2001) and Acinetobacter 
baumannii (Houang et al., 2003). There is clear evidence for lateral gene transfer of 
ARR-2. 
 
1.5.4.2 Structural 
Although there is no significant DNA or protein sequence similarity between ARR 
and other ADP-ribosyltransferases there is definite structural homology. Based on 
their crystal structures, ADP-ribosyltransferases are divided into two classes. Class I, 
which includes the PARPs and diphtheria toxin, and Class II, which includes ART2 
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and VIP2 toxin (Baysarowich et al., 2008). The two classes share a common NAD+-
binding core made up of two adjoining β-sheets made up of five β-strands. 
Distinguishing features between the classes included a variable number of α-helices 
and distinct motifs, H-Y-E in Class I and R-S-E in Class II. 
 
Structural alignments show that ARR shows structural similarities with Class I ADP-
ribosyltransferases (Baysarowich et al., 2008). ARR appears to represent the 
minimum unit required for ADP-ribosyltransferase activity. Although sequence 
alignment software fails to reveal the common H-Y-E motif found in Class I ADP-
ribosyltransferases, a structure-based comparison revealed two residues (H19 and 
Y49) likely to serve the same NAD+-binding function in ARR. H19 is present in β1 
and Y49 in β3. Mutational studies have shown that these two residues are essential 
for enzyme function (Baysarowich et al., 2008). 
 
There is a single glutamic acid on the front edge of β6 which is conserved in all 
previously known ADP-ribosyltransferases. This residue is believed to be absolutely 
necessary for ADP-ribosyltransferase activity; however, this residue is not present in 
ARR (Baysarowich et al., 2008). This residue is necessary for stabilising the 
predicted oxocarbenium ion in the transition-state of ADP-ribosylation. In ARR it 
appears that the aspartic acid residue in position 84 which is in the loop connecting 
β5 to β6 performs this function. 
 
1.5.5 Heat stability 
Previous studies have shown that ARR functions optimally at 45 °C (Gianniosis, 
2007) and that the enzyme is able to function after heating to 100 °C (Quan et al., 
1997). This indicates that ARR is a thermostable protein. Many species of 
Mycobacterium are able to withstand high temperatures as a consequence of their 
hardy cell walls. Thermophilic bacteria have been shown to have extensive ADP-
ribosylation systems (Faraone-Mennella et al., 2006). It is not clear whether there is a 
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link between ADP-ribosylation systems and the ability of a bacterium to persist at 
high temperatures. 
 
1.5.6 Changes in cell wall morphology 
Previous studies have shown that the expression of ARR changes cell wall 
morphology in both Gram-negative and Gram-positive bacteria. This has been shown 
by the formation of long filaments in E. coli expressing ARR (Puhaca, 2005; 
Gianniosis, 2007) and a change in colony morphology in R. equi (Quan, 1997). 
 
The reason for this change in cell wall morphology is not clear. It appears to be 
independent of ADP-ribosylation of rifampicin and uses ARR residues, distinct to 
those involved in rifampicin binding, in binding this target (Puhaca, 2005). This 
second function of ARR would explain the extreme plasticity of binding to rifampicin 
as well as the large number of ARR-like sequences from environmental isolates 
where there has been no obvious human pressure (Baysarowich et al., 2008). 
 
1.5.7 A possible threat to TB treatment 
Baysarowich found that the majority of arr-like sequences were present either as 
integrons or alongside transposable sequence. This suggests a high level of lateral 
gene transfer of this gene. It has been shown that mycobacteria can acquire 
pathogenicity factors through lateral gene transfer (Paustian et al., 2005). With the 
high number of HIV patients infected with TB and other opportunistic pathogens, it is 
becoming increasingly likely that M. tuberculosis will come into contact with another 
pathogen carrying arr as a mobile genetic element and gene transfer would be 
possible. 
 
Should arr be transferred to M. tuberculosis the resultant strain would pose a huge 
threat to the treatment of TB with rifampicin as a frontline drug. Recently, an 
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orthologue of rifampicin, in which the acetate group on carbon 25 is substituted with 
a carbamate group, was found to be effective at disabling bacterial transcription but 
could not be used as a substrate for ARR (Combrink et al., 2007) . Should strains of 
M. tuberculosis containing the arr gene arise, this compound will be invaluable in 
treating the resulting rifampicin resistant TB. 
 
1.6 Aims of this project 
This project aims to optimize over-expression and purification of ARR, as well as 
characterize ARR biochemically by use of fluorescence and circular dichroism 
spectroscopy, as very little biochemical information is available on ARR. It also aims 
to further investigate changes in cell wall morphology by microscopy and, if possible, 
explain these changes. 
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2 Materials and Methods 
2.1 Bacterial strains 
Bacterial strains used in this work are listed in Table 2.1. 
 
2.2 Plasmids 
pQE-30 was used for protein expression. pGEM-T Easy was used for sequencing. 
(see Table 2.2). 
 
2.3 Plasmid purification 
Plasmid purification was carried out using the Genejet Miniprep Kit (Fermentas). 
This kit is based on the alkaline lysis method of Birnboin and Doly (Birnboin and 
Doly, 1979). Alkaline lysis (by sodium dodecyl sulphate and sodium hydroxide) is 
used to lyse cells and denature cell components. When the lysate is neutralized 
plasmid DNA is able to renature because of its small size and also because it has been 
somewhat protected from denaturation due to its circular nature. Once plasmid DNA 
has renatured, it resolubilizes while all other denatured cell components 
(chromosomal DNA, proteins, lipids) remain insoluble and are pelleted out. The 
plasmid DNA is then purified further by binding the DNA to a silica membrane in the 
presence of high concentrations of chaotropic salt (in this case guanidinium chloride). 
After an ethanol rinse, the DNA is eluted from the membrane under low salt 
conditions. 
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Table 2.1 Bacterial strains used in this work. 
Species Strain Selection Markers Source 
E. coli 
   
 
MM2942 - E. Dabbs 
 
BL21 (DE3) pLysS - Promega 
 SG13009 (pREP) Kanamycin 
resistance 
Qiagen 
 E. cloni - Lucigen 
M. smegmatis    
 DSM 43657 - E. Dabbs 
 DSM 43657Km1 Kanamycin 
resistance 
S. Quan 
 
 
 
 
Table 2.2 Plasmids used in this work 
Plasmid Insert Size Source 
pQE-30 - ~ 3.5 Kb Qiagen 
pQE-30 ARR ~ 4 Kb J. Burke 
pGEM-T Easy 
 
- ~ 3 Kb Promega 
pGEM-T Easy pQE-30 ARR 
fragment 
~ 3.6 Kb This work 
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2.3.1 Determination of DNA concentrations 
DNA concentrations were determined spectrophotometrically using the NanoDrop 
ND-1000 spectrophotometer. The absorbance at 260 nm was used given that 50 
µg/ml of double stranded DNA has an A260 of 1.0. This value is based on the Beer 
Lambert law and the extinction coefficient of double stranded DNA. 
2.3.2 Agarose gel electrophoresis 
Gels of 1% agarose were prepared using 1 X TAE buffer (40 mM Tris acetate; 1 mM 
EDTA). Two microlitres of ethidium bromide (1 mg/ml) was added to 50 ml of gel 
solution.  Samples were loaded with 6 X Sample Loading Buffer Fermentas (10 mM 
Tris, 0.03% bromophenol blue, 0.03% xylene cyanol FF, 60% glycerol, 60 mM 
EDTA). Gels were electrophoresed in 1 X TAE buffer until the bromophenol blue 
band of the tracking dye in the sample buffer had electrophoresed to approximately 3 
cm of the bottom edge of the gel. Gels were viewed under a UV-transilluminator at 
320 nm. 
 
2.4 Polymerase chain reaction (PCR) 
PCR is a commonly used molecular biological technique used to produce large 
amounts of DNA from a small amount of template through amplification using DNA-
dependent DNA polymerase (Mullis et al., 1986).  
 
2.4.1 Oligonucleotide primer design 
DNA-dependent DNA polymerase requires a short DNA primer to function. This 
primer is complimentary to the template and upon annealing to the template is 
extended in a template dependent manner by the polymerase enzyme. Primers were 
designed to bind about 75 bp away from the T-overhangs in pGEM-T Easy. Primers 
were checked for propensity to form secondary structures and primer dimers using 
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the GeneRunner version 3.01 software (copyright © 1996 Hastings Software Inc). 
These primers were named pQE-30seq forward and pQE-30seq reverse. 
 
2.4.2 PCR of the ARR fragment from pQE-30 
The best annealing temperature was determined by thermocycling eight reactions 
(pQE-30seq forward and reverse 2 µM each; pQE-30seq reverse; template 100 ng/µl; 
1X Fermentas Mastermix) through the same cycle but with varying annealing 
temperatures in a BioRAD MJ mini thermocycler. The annealing temperatures used 
were: 60 ºC; 59.3 ºC; 58 ºC; 56.2 ºC; 54 ºC; 52.1 ºC; 50.8 ºC and 50 ºC. These 
temperatures were chosen by taking the average TM of the forward and reverse 
primers and using a gradient that ranged from ±5 ºC of this average. These eight 
reactions were thermocycled using plasmid extracted from E. coli BL21 (DE3) pLysS 
and MM2942 cells to determine which was a more efficient template. 
 
In order to obtain the highest yield of product with the lowest amount of non-specific 
amplification, various parameters were tested (Table 2.3). These included MgCl2 
concentration, template DNA concentration and extension time during cycling. 
 
Thermocyling conditions were as follows: initial denaturation at 94 °C for 1 minute, 
30 cycles of denaturation at 94 °C for 30 seconds, primer annealing at 50-60 °C for 
30 seconds, and extension at 72 °C for 30 seconds to 60 seconds, and final extension 
at 72 °C for 5 minutes. PCR products were further purified using the Promega Wizard 
SV Gel and PCR Clean Up System and subsequently evaluated by agarose gel 
elctrophoresis on a 1% gel. 
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Table 2.3 Components of PCR reactions for amplification of the ARR fragment from 
pQE-30. 
Component Reaction 1 Reaction 2 Reaction 3 Reaction 4 
dNTP Mix 0.2 µM 0.2 µM 0.2 µM 0.2 µM 
MgCl2 1 mM 2 mM 1 mM 2 mM 
Forward Primer 1 µM 1 µM 1 µM 1 µM 
Reverse Primer 1 µM 1 µM 1 µM 1 µM 
Template DNA 50 ng 50 ng 150 ng 150 ng 
Taq reaction buffer To 1X To 1X To 1X To 1X 
Taq polymerase 5 U 5 U 5 U 5 U 
Nuclease free water To 50 µL To 50 µL To 50 µL To 50 µL 
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2.5 Cloning of ARR fragment from pQE-30 into pGEM-T Easy 
Due to difficulties in sequencing the ARR insert in pQE-30 it was necessary to 
sequence the insert in an alternative vector. pGEM-T Easy (Promega) is a TA cloning 
vector. In addition to a multiple cloning sites, the vector has 5′ T-overhangs. 
Undigested PCR products can be ligated to these overhangs because polymerases, 
which do not have 3′-5′ editing activity, add 3′ terminal adenosine bases during PCR 
(Clark, 1988). Taq is one such polymerase. 
 
2.5.1 Ligation 
Ligation reactions were set up as follows: 1 µl Promega T4 Ligase (3 Weiss units/µl); 
5 µl Ligation buffer (2 X); 1 µl pGEM-T Easy (50 ng/µl); 2 µl ARR insert (50 ng/µl); 
1 µl nuclease free water. The reactions were left at 20 °C for 18 hours. 
 
2.5.2 Transformation of competent cells with plasmid DNA 
Transformations were carried out using the heat-shock method. Competent cells (as 
listed in Table 2.1) were thawed on ice. Approximately 50 ng of chilled DNA was 
added to 50 µl of cells. The cells were then incubated on ice for 30 min and then heat-
shocked at 42 °C for 45 sec and placed back on ice for a further 5 min. After this,  
500 µl of SOC (Super Optimal broth with Catabolite) media Novagen (2 % typtone, 
0.5 % yeast, 10 mM NaCl, 2.5mM KCl, 10 mM MgCl2, 40 mM glucose),  was added 
and the cells were incubated with agitation at 37 °C for one hour to allow selection 
genes to be expressed. 
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Although, until recently, the exact mechanism by which heat-shock improved 
transformation efficiencies was unknown it has now been shown that the heat pulse 
from 0°C to 42°C back to 0°C forms pores in the membrane by causing the release of 
lipids from the cell surface and reduces the cell wall potential allowing the DNA to 
pass through (Panja et al., 2008). 
 
2.5.3 Confirmation of positive clones 
pGEM-T Easy containing the ARR fragment was transformed into E. cloni cells 
(Lucigen) and the resultant transformants were screened for plasmid presence by 
overnight growth on Luria-Bertani broth (LB) Agar (1% tryptone; 0.5% yeast extract; 
0.5% NaCl; 1.5% agar) supplemented with 100 µg/ml ampicillin. These colonies 
were then screened for the insert by colony PCR. Colony PCR was performed using 
single colonies, 1 µM each of T7 forward primer and M13 reverse primer and 
Fermentas PCR Master Mix. 
 
 
2.6 Sequencing of ARR fragment 
Plasmid DNA was extracted from E. cloni cells transformed with pGEM-T Easy 
containing the ARR fragment. This DNA was sent to Inqaba Biotec (Pretoria, South 
Africa) for sequencing using the universal T7 forward and M13 reverse primers. 
 
2.7 Induction studies 
Heterologous expression of genes in pQE-30 is under the control of the phage T5 
promoter coupled to two lac operators. This system is inducible by isopropyl β-D-1-
thiogalactopyranoside (IPTG). Although the T5 promoter is recognised by E. coli 
RNA polymerase and can thus be used in any E. coli strain, Qiagen advise that best 
results are obtained using Qiagen cell lines specifically designed for use with the pQE 
vector range (QIA-Express Cloning Manual). One of these cell lines is E. coli 
SG13009 (pREP). 
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2.7.1 Preparation of competent E. coli SG13009 (pREP) cells 
This methodology is based on that of Hanahan (1983) and uses low temperatures and 
divalent ions to induce competency in cells. An overnight culture of E. coli SG13009 
(pREP) cells was grown in LB supplemented with 25 µg/ml kanamycin (to maintain 
the pREP plasmid) at 37 ºC with shaking at 250 rpm. 3ml of this culture was added to 
50 ml fresh LB and grown until the optical density at 600 nm was 0.6. The cells were 
then decanted into pre-cooled centrifuge tubes and left on ice for 15 minutes 
 
The chilled cells were pelleted by centrifugation at 2500 rpm in a chilled Sorvall SS-
34 rotor for 12 minutes. The supernatant was discarded and the cells were 
resuspended in 15 ml transformation buffer (10 mM Mes pH 6.2, 100 mM KCl,       
45 mM MnCl2, 10 mM CaCl2, 3 mM HACoCl3) and chilled on ice for 15 minutes 
then centrifuged for 10 minutes at 2500 rpm in a chilled Sorvall SS-34 rotor. The 
supernatant was discarded and the cells were resuspended 4 ml of transformation 
buffer. Dimethylformamide (DMF) was added to a concentration of 3.5 %. The cells 
were placed on ice for 5 minutes and then 140 µl of 1 M DTT was added. After 
chilling on ice for a further 10 minutes, 140 µl of DMF was added and the cells were 
chilled for 5 minutes before aliquoting. 
 
2.7.2 Induction conditions 
Cells (E. coli MM2942; BL21 (DE3) pLysS and SG13009 (pREP)) were grown in 
LB (1% tryptone; 0.5% NaCl; 0.5% yeast extract) at 37 ºC overnight shaking at     
250 rpm. A 100 X dilution of the overnight culture was prepared in LB and grown 
until the optical density at 600 nm reached 0.4 (early log phase), 0.6 (mid log phase) 
and 0.8 (late log phase). Cells were then induced with either 0.5 or 1 mM IPTG and 
samples taken every 2 hours (see Table 2.4). These samples were then prepared for 
SDS-PAGE and electrophoresed as described below. 
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Table 2.4 Conditions examined in induction study. 
Growth stage Cell Lines Induction times 
(Hours) 
IPTG 
concentrations 
Early- log phase E. coli BL21 (DE3) 
pLysS;  
E. coli MM294;  
E. coli SG13009 
(pREP) 
0; 2; 4; 6; 8; >10 0.5mM; 1mM 
Mid-log phase E. coli BL21 (DE3) 
pLysS;  
E. coli MM294;  
E. coli SG13009 
(pREP) 
0; 2; 4; 6; 8; >10 0.5mM; 1mM 
Late-log phase E. coli BL21 (DE3) 
pLysS;  
E. coli MM294;  
E. coli SG13009 
(pREP) 
0; 2; 4; 6; 8; >10 0.5mM; 1mM 
42 
 
 
2.7.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed by the discontinuous method described by Laemmli 
(1970). A 15 % acrylamide separating gel was prepared with 0.375 M Tris/HCl buffer 
(pH 8.8) and 0.1% SDS. A 4% acrylamide stacking gel was prepared with 0.0625 M 
Tris/HCl buffer (pH 6.8) and 0.1% SDS. Samples were prepared for electrophoresis 
by diluting them 1:1 with SDS sample buffer (2% SDS, 5% β-mercaptoethanol, 10% 
glycerol and 0.02% bromophenol blue) and heating at 95 ºC for 5 minutes. Molecular 
weight markers were also prepared in the same manner. 
 
After application of samples to wells, gels were electrophoresed at 120 V until the 
bromophenol blue had migrated to approximately 1 cm of the bottom of the gel. The 
electrophoresis buffer was made up of 0.025 M Tris and 0.192 glycine buffer (pH 
8.6) containing 1% SDS. After electrophoresis gels were stained (2% Coomassie blue 
R250, 13.3% glacial acetic acid and 18.75% ethanol) and destained (40% ethanol and 
10 % glacial acetic acid). 
 
2.8 Purification of ARR 
2.8.1 Overexpression of ARR 
E. coli BL21 (DE3) pLysS cells containing the pQE-30 plasmid with ARR insert 
were grown in LB, supplemented with 100 µg/ml  ampicillin, overnight at 37 ºC with 
shaking at 250 rpm. Four litres of a 100 X dilution of this culture were made up in 
fresh ampicillin-supplemented LB and grown under the same conditions until the 
optical density at 600 nm reached 0.6. At this stage, IPTG was added to a final 
concentration of 1 mM. The cells were allowed to grow for 18 hours. 
 
The cells which had been induced overnight were pelleted by a 20 min centrifugation 
at 5 000 rpm in a Sorvall SLA-3000 rotor and resuspended in 1/100 the volume 
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phosphate buffer (50 mM Na2HPO4 pH7.5). Resuspensed cells were disrupted by five 
cycles of 30 second pulse sonication and centrifuged at 10 000 rpm for 20 min in a 
chilled Sorvall SS-34 rotor in order to separate the soluble component of the cell from 
the insoluble component. The insoluble pellet was discarded and the soluble 
supernatant was used in purification. 
 
2.8.2 Immobilised metal affinity chromatography (IMAC) 
The pQE-30 vector expresses a 6 X His tag upstream of the multiple cloning site 
resulting in N-terminally His-tagged proteins. IMAC is the most commonly used 
purification method of His-tagged proteins and Ni2+ columns are frequently used. 
However, there can be problems of low protein purity and metal leaching from the 
column. Columns charged with cobalt claim to minimize these problems. His-Bind 
resin (Novagen) is a Ni-NTA (nickel-nitrilotriacetic acid) resin. His-pur Cobalt resin 
(Pierce) is a tetradentate, cobalt charged, 6% cross-linked agarose bead resin.  
 
2.8.2.1 His-Bind Purification 
A 10 ml column of His-Bind resin was charged according to manufacturer’s 
instructions and equilibrated with ten column volumes of binding buffer (0.5 M 
NaCl; 20 mM Tris HCl pH 7.9; 5 mM imidazole). After loading the soluble cell 
fraction 5 column volumes of binding buffer were run through the column. The 
column was then washed with ten column volumes wash buffer (0.5 mM NaCl;       
20 mM Tris HCl pH 7.9; 60 mM imidazole) The protein was eluted using five 
column volumes elution buffer (0.5 M NaCl; 20 mM Tris-HCl pH 7.9; 1 M 
imidazole). 
 
2.8.2.2 His-pur Purification 
A 5 ml His-pur cobalt resin column was set up according to the manufacturer’s 
instructions. The column was then equilibrated with 10 column volumes equilibration 
buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, pH7.4). After 
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equilibration, the ARR containing soluble cell fraction was loaded onto the column 
and allowed to flow by gravity. Once the soluble fraction had passed through the 
column, another 10 column volumes of equilibration buffer were passed through the 
column to remove any proteins non-specifically bound to the column and finally 
ARR was eluted from the column using four column volumes of elution buffer (50 
mM Na2HPO4, 300 mM NaCl, 150 mM imidazole, pH 7.4). 
 
2.8.3 Determination of ARR purity and concentration 
The purity of ARR was determined by SDS-PAGE. Protein concentration was 
determined spectrophotometrically using the Beer-Lambert law (Equation 1) 
 
A = ελcl                                                                 (1) 
 
where A is absorbance, ελ is the molar extinction coefficient at wavelength λ, c is 
concentration and l is path length. In order to determine the molar extinction 
coefficient of ARR at 280 nm the method of Perkins (1986) was used (Equation 2). 
This method uses the known molar coefficients of the amino acids tryptophan (5550 
M-1cm-1), tyrosine (1340 M-1cm-1) and cysteine (150 M-1cm-1) at 280 nm. 
 
ε(280)(M-1cm-1) = 5550 ΣTrp + 1340 ΣTyr + 150 ΣCys                  (2) 
 
By this calculation, the molar extinction coefficient of ARR at 280 nm is calculated 
as 18450 (M-1cm-1). 
 
2.9 Spectroscopic studies 
2.9.1 Far-UV circular dichroism (CD) 
CD spectroscopy reports the difference in absorbance of left- and right-handed 
circularly polarized light by optically active modules. In proteins, there are two 
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primary optically active elements; the peptide backbone (active between 250 and   
170 nm) and the aromatic side chains of amino acids (active between 300 and 250 
nm). Far-UV CD (that of the backbone) offers valuable information about a protein’s 
secondary structure and gives an indication of the α-helical, β-strand and random coil 
content (For a review of the use of circular dichroism of proteins see Yang et al., 
1986 and Woody, 1995). 
 
Far-UV CD spectra were generated between 180 and 250 nm with a cuvette of 2 mm. 
The spectra were averages of ten accumulations. Thermal unfolding curves were 
generated by tracking the level of ellipticity at 222 nm while ramping the temperature 
of the sample at 1 ºC/min from 5 ºC to 85 ºC. ARR was dialyzed into 50 mM 
phosphate buffer (pH 7.5) to remove all chloride ions before all CD measurements 
were recorded. 
 
2.9.2 Fluorescence spectroscopy 
Fluorescent molecules are able to absorb light of a certain wavelength (excitation 
wavelength) and emit some of this light at a different wavelength (emission 
wavelength). This phenomenon, known as fluorescence, is due to electrons entering a 
higher energy state as a result of energy from the absorbed light. These electrons fall 
back to their lower energy state, causing energy to be released in the form of light. 
Because the light emitted is always of a lower energy (higher wavelength) than the 
light absorbed, the excitation wavelength of a molecule will always be shorter than 
the emission wavelength (Lakowicz, 1983). 
 
Tryptophan is a fluorophore which is very sensitive to its local environment and can 
thus be used as a local probe in a protein. From the crystal structure of ARR it can be 
deduced that the tryptophan at position 57 is solvent exposed in unbound ARR but 
buried when ARR is bound to rifampicin (see Figure 2.1). It may thus be possible to 
monitor the amount of ARR bound to rifampicin versus the unbound ARR in a 
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solution with rifampicin by monitoring the solution’s fluorescence at 295 nm where 
only tryptophan is contributing to the fluorescence. 
 
All fluorescence measurements were carried out on a Perkin-Elmer fluorimeter with 
slit-widths set to 5 nm. ARR was dialyzed into 50 mM phosphate buffer (pH 7.5) 
prior to fluorescence measurements. Intrinsic fluorescence of ARR was measured at 
280 nm (tyrosine and tryptophan fluorescence) and 295 nm (tryptophan fluorescence) 
excitation wavelengths. For binding studies the fluorescence was measured at 295 nm 
excitation wavelength. Binding was assessed with 10 µM ARR and between 24 and 
212 µM rifampicin. 
 
To ascertain if rifampicin was absorbing any of the excitation or emission light (inner 
filter effects). An absorbance spectrum of rifampicin was constructed between       
190 nm and 400 nm. 
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Figure 2.1 Ribbon diagram representing the crystal structure of  ARR with 
tryptophans highlighted. Rifampicin is shown in yellow. The two tryptophans (W57 
and W115) are shown in blue. Figure generated using Swiss PDB Viewer (Kaplan 
and Littlejohn, 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
W115 
W57 
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2.10 Microscopic studies 
Microscopic studies were undertaken to asses the possible role of ARR in cell 
morphology. In order to do this both E. coli and M. smegmatis strains were examined. 
The E. coli strain examined was BL21 (DE3) pLysS, one containing pQE-30 
expressing ARR and one which did not. The M. smegmatis strains used were the wild 
type strain from which ARR was first isolated (DSM 43657) and a strain which 
carries a kanamycin resistance cassette disrupting the ARR gene (DSM 43657Kam1). 
 
2.10.1 Light microscopy 
E. coli strains were grown overnight in LB at 37 ºC with shaking at 250 rpm. M. 
smegmatis were grown for 3 days in Heart Brain Infusion broth at 37 ºC with shaking 
at 250 rpm. A loopful of each culture was placed onto individual glass slides and 
heat-fixed using an open flame. E. coli cells were stained using crystal violet, while 
M. smegmatis cells were stained with saffron (mycobacterial cell walls are 
impermeable to crystal violet). Slides were viewed with 1000 X magnification. 
 
2.10.2 Scanning electron microscopy 
Cells were cultured as described above for light microscopy. Five microlitres of each 
culture was dropped onto individual copper grids with carbon coating and allowed to 
dry. Once dry, 5 µl of a saturated uranyl acetate solution was dropped onto the grids 
and air-dried. The grids were viewed on a J100 scanning electron microscope 
(Electron Microscope Unit, University of the Witwatersrand, Johannesburg, South 
Africa). 
 
2.11 Determination of heat tolerance in E. coli 
To determine whether the changes in E. coli cell wall morphology caused by ARR 
gave the cells increased heat tolerance, E. coli BL21 (DE3) pLysS cells expressing 
ARR and E. coli BL21 (DE3) pLysS cells not expressing ARR were monitored for 
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growth at 50 ºC. This was done in LB with shaking at 250 rpm. Growth was 
inspected visually after 24 hours. 
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Chapter 3 Results 
3.1 Plasmid extraction 
pQE-30 (containing the ARR insert) was successfully extracted from E. coli 
BL21(DE3) pLysS and E. coli MM2942 cells. The plasmids did not appear to be 
contaminated by chromosomal DNA as shown by agarose gel electrophoresis (see 
Figure 3a and b). The size of the plasmid was not estimated used agarose gel 
electrophoresis as the plasmid was still circularized. The concentration of plasmid 
from the BL21 cells was spectrophotometrically determined to be 144.3 ng/µl and 
that of the plasmid obtained from the MM294 cells was 100.2  ng/µl. 
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                            (a)                                                                    (b) 
 
                                                        
                  
Figure 3.1: Agarose gel electrophoresis of pQE-30 containing ARR insert (a) Lane 1, 
Fermentas Generuler 100 bp DNA ladder; Lane 2, pQE-30 containing ARR insert 
purified from E. coli BL21 (DE3) pLysS cells (b) Lane 1, Fermentas ZipRuler 1; 
Lane 2, pQE-30 purified from E. coli MM2942 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1     2  1     2 
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3.2 PCR 
3.2.1 Oligonucleotide primer design 
The forward and reverse primers (see Table 3.1) were designed to amplify the ARR 
fragment from pQE-30 and did not show a significant propensity for forming 
secondary structures or primer dimers. 
 
Table 3.1 Sequence of pQE-30seq primers. 
Primer Sequence 
pQE-30seq Forward GGAGAAATTAACTATGAGAGG 
pQE-30seq Reverse GTTCTGAGGTCATTACTGG 
 
 
3.2.2 Optimisation of reaction conditions 
It was found that plasmid extracted from E. coli BL21 (DE3) pLysS with an 
annealing temperature of 58 ºC gave a reasonable yield of product without excessive 
nonspecific product (see Figure 3.2a and b). It was still necessary to reduce non-
specific binding. Reaction mix 1(Table 2.3) was found to give the purest product (see 
Figure 3.3). The amplicon was further purified (see Figure 3.4). The expected size of 
the amplicon was about 650 bp. 
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(a)                                                                             
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Agarose gel elecrophoresis of thermal gradient PCR (a) PCR products 
when template plasmid from E. coli MM2942 was used: Lane 1, Fermentas Generuler 
100 bp DNA Ladder; Lane 2, 60 ºC annealing temperature; Lane 3, 59.3 ºC annealing 
temperature; Lane 4, 58 ºC annealing temperature; Lane 5, 56.2 ºC annealing 
temperature; Lane 6, 54 ºC annealing temperature, Lane 7, 52.1 ºC; Lane 8, 50.8 ºC; 
Lane 9, 50 ºC annealing temperature (b) PCR product when template plasmid from E. 
coli BL21 (DE3) pLysS was used. Lane designation same as for (a) 
700 bp 
600 bp 
700 bp 
600 bp 
  1   2    3     4    5   6    7    8    9 
  1         2    3  4   5   6    7   8   9    
ARR Insert 
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Figure 3.3 Agarose gel electrophoresis of PCR products Lane 1, Fermentas 
Generuler 100 bp DNA Ladder; Lane 2, reaction 1; Lane 3, reaction 2; Lane 4, 
reaction 3; Lane 5, reaction 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  1     2      3       4       5      6       7 
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Figure 3.4 Agarose gel electrophoresis of PCR product after further purification Lane 
1, Fermentas ZipRuler 1; Lanes 2 and 3 PCR product of arr insert after optimization 
and clean up. 
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3.3 Cloning 
Eleven transformants were randomly selected after initial screening for the presence 
of the ARR insert. Of these eleven, three were found to contain the ARR insert by 
colony PCR. One of these was randomly selected for sequencing. 
 
3.4 Sequencing 
The chromatogram was checked for errors and the insert was confirmed as the known 
arr sequence with no alterations. 
 
3.5 Over-expression 
No detectible over-expression of ARR using the pQE-30 vector was found using E. 
coli MM2942 (See Figures 3.5 and 3.6), BL21 (DE3) pLysS (see Figures 3.7, 3.8 and 
3.9) or SG13009 (data not shown). 
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Figure 3.5 SDS-PAGE of whole cell extracts from induction study using E. coli 
MM2942 induced at mid-log phase. Lanes 1-7 0.5 mM IPTG. Lanes 8-13 1 mM 
IPTG. Lane 1, Fermentas Protein Marker A; Lane 2, overnight induction; Lane 3, 8 
hour induction; Lane 4, 6 hour induction; Lane 5, 4 hour induction; Lane 6, 2 hour 
induction; Lane 7, 0 hour induction; Lane 8, >16 hours induction; Lane 9, 8 hour 
induction; Lane 10, 6 hour induction; Lane 11, 4 hour induction; Lane 12, 2 hour 
induction; Lane 13, 0 hour induction. 
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Figure 3.6 SDS-PAGE of whole cell extracts from induction study using E. coli 
MM2942 cells induced at late-log phase. Lane 1, 0 hour induction; Lane 2, 2 hour 
induction; Lane 3, 4 hour induction; Lane 4, 6 hour induction; Lane 5, 8 hour 
induction; Lane 6, >16 hours induction; Lane 7, Fermentas Protein Marker A; Lane 8, 
>16 hours induction; Lane 9, 8 hour induction; Lane 10, 6 hour induction; Lane 11, 4 
hour induction; Lane 12, 2 hour induction; Lane 13, 0 hour induction. 
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Figure 3.7 SDS-PAGE of whole cell extracts from induction study using E. coli 
BL21 (DE3) pLysS cells induced with 1mM IPTG at mid-log phase. Lane 1, 0 hours 
induction; Lane 2, 2 hours induction; Lane 3. 4 hours induction; Lane 4, 6 hours 
induction; Lane 5, 8 hours induction; Lane 6, >16 hours induction; Lane 7 Fermentas 
Protein Marker . 
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Figure 3.8 SDS-PAGE of whole cell extracts from induction study using E. coli 
BL21 (DE3) pLysS induced with 0.5 mM IPTG. Lane 1, 0 hour induction; Lane 2, 2 
hour induction; Lane 3, 4 hour induction; Lane 4, 6 hour induction; Lane 5, 8 hour 
induction; Lane 6, overnight induction; Lane 7, Fermentas Protein Marker A; Lane 8, 
overnight induction; Lane 9, 8 hour induction; Lane 10, 6 hour induction; Lane 11, 4 
hour induction; Lane 12, 2 hour induction; Lane 13, 0 hour induction. 
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Figure 3.9 SDS-PAGE of whole cell extracts from induction study using E. coli 
BL21 (DE3) pLysS cells induced with 1 mM IPTG at late-log phase. Lane 1, 
Overnight induction; Lane 2, 8 hour induction; Lane 3, 6 hour induction; Lane 4, 
Fermentas Protein Marker A; Lane 5, 4 hour induction; Lane 6, 2 hour induction; 
Lane 7, 0 hour induction. 
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3.6 Purification 
3.6.1 His-Bind purification 
Purification was successful (See Figure 3.10) although ARR was heavily 
contaminated with other proteins (less than 85% purity by densitometry). The 
concentration was approximately 10 µM. Attempts to remove contaminating protein 
using a salt gradient through the His-Bind column and size exclusion led to 
significant losses of protein. His-Bind was abandoned as a purification method. 
 
3.6.2 His-Pur  purification 
Purification was successful (See Figure 3.11). ARR was pure enough for further 
applications (greater than 95% purity by densitometry). The concentration was 27 µM 
but was diluted to a 10 µM working stock for further use. 
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Figure 3.10 SDS-PAGE of ARR expressed in E. coli (DE3) pLysS purified using 
His-Bind resin. Lane 1, Fermentas Protein Marker A; Lane 2, Whole cell extract; 
Lane 3, ARR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 SDS-PAGE of ARR expressed in E. coli (DE3) pLysS purified using 
His-Pur resin. Lane 1, Fermentas Protein Marker A; Lane 2, and 3 ARR; Lanes 4 and 
5 whole cell extract. 
25 kDa 
18 kDa 
25 kDa 
18 kDa 
1       2                                    3 
1          2      3           4          5 
64 
 
 
 
3.7 Spectroscopic studies 
 3.7.1 Far-UV Circular Dichroism 
The spectrum for native ARR (See Figure 3.12) showed minima at 210 nm and 222 
nm with the greater minima at 210 nm. The heat-denatured ARR spectrum showed a 
similar shape but the degree of ellipticity was more than half that of the native ARR 
(8 mdeg.cm2.dm-1 compared with 21 mdeg.cm2.dm-1). 
 
 
Figure 3.12 Far-UV circular dichroism spectra of 10 µM native and heat-denatured 
and native ARR. Red spectrum: 10 µM native ARR, green spectrum 10 µM heat 
denatured ARR. 
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3.7.2 Thermal unfolding 
During thermal unfolding the degree of ellipticity decreased from 20 mdeg.cm2.dm-1 
to 8 mdeg.cm2.dm-1. During cooling the degree of ellipticity did not significantly 
change. The TM (the temperature at which half of the protein concentration is 
denatured) of ARR is approximately 52 ºC (see Figure 3.13). 
 
 
 
Figure 3.13 Thermal unfolding curve using far-UV CD as a probe of 10 µM ARR. 
Pink curve 10 µM ARR unfolding, blue curve 10 µM ARR Refolding. 
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3.7.3 Fluorescence 
At an excitation wavelength of 280 nm (tyrosine and tryptophan fluorescence) ARR 
exhibited an emission maximum at approximately 350 nm and an intensity of        
410 (arbitrary units). At an excitation wavelength of 295 nm (tryptophan 
fluorescence) the emission maximum wavelength remained unchanged at 350 nm 
while the intensity dropped to 300 (arbitrary units). (See Figure 3.14)  
 
 
Figure 3.14 Fluorescence spectra of 10 µM ARR. Blue spectrum: 295 nm excitation 
wavelength, red spectrum: 280 nm excitation wavelength. 
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3.7.4 Binding Assay 
Definite red shifting of the emission maxima was seen with increasing levels of 
rifampicin added to the solution (See Figure 3.15). The intensity increased as the 
rifampicin was increased until 58µl beyond this amount the intensity began to 
decrease. The absorbance of the added rifampicin at 280nm ranged from 0.14 O.D. to 
1.8 O.D. (data not shown). Rifampicin showed no intrinsic fluorescence but strong 
absorbance at 295 nm (data not shown). 
 
 
 
Figure 3.15 Fluorescence spectra of binding assay using 10 µM ARR and varying 
concentrations of rifampicin. Light blue spectrum: 24 µM rifampicin, red spectrum: 
10 µM ARR, green spectrum: 10 µM ARR/ 24 µM rifampicin, yellow spectrum:      
10 µM ARR/ 58 µM rifampicin, dark blue spectrum: 10 µM ARR/ 106 µM 
rifampicin, pink spectrum: 10 µM ARR/ 212 µM rifampicin. 
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3.8 Microscopic studies 
3.8.1 Light microscopy 
E. coli cells expressing ARR were longer than those not expressing ARR (See Figure 
3.16 and 3.17). No observable change in any other cell features such as width, 
branching or overall shape. M. smegmatis cells expressing ARR showed branching 
compared to those not expressing ARR which were not branched (See Figure 3.18 
and 3.19). There were no other visible changes to cell features. 
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Figure 3.16 a and b Light micrographs of E. coli BL21 (DE3) pLysS cells not 
expressing ARR. 
(a) 
(b) 
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Figure 3.17 a and b Light micrographs of E. coli BL21 transformed with pQE-30 
containing ARR insert.  
(a) 
(b) 
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Figure 3.18 Light micrograph of M. smegmatis DSM 43657Km1. These cells do not 
express ARR. 
 
 
Figure 3.19 Light micrograph of M. smegmatis DSM 43657. These cells express 
ARR. 
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3.8.2  Electron microscopy 
The results obtained from light microscopy were confirmed using electron 
microscopy. E. coli expressing ARR were longer than their non ARR-expressing 
counterparts. M. smegmatis cells which expressed ARR were branching while those 
which did not express ARR did not show branching (See Figures 3.20, 3.21, 3.22 and 
3.23). 
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Figure 3.20 Transmission electron micrographs of M. smegmatis DSM 43657Km1 
(a) 15 000 X magnification (b) 15 000 X magnification. 
(a) 
(b) 
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Figure 3.21 Transmission electron micrographs of M. smegmatis DSM 43657          
(a) 15000 X magnification (b) 15 000 X magnification (c) 15 000 X magnification. 
(a) 
(b) 
(c) 
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Figure 3.22 Transmission electron micrographs of E. coli BL21 (DE3) pLysS (a) 
8000 X magnification (b) 5 000 X magnification (c) 10 000 X magnification. 
(a) 
(b) 
(c) 
76 
 
 
 
 
 
 
Figure 3.23 Transmission electron micrographs of E. coli expressing ARR (a) 5 000 
X magnification (b) 8 000 X magnification (c) 8 000 X magnification. 
(a) 
(b) 
(c) 
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3.9 Determination of heat tolerance in E. coli. 
There appeared to be no significant change to heat tolerance of E. coli expressing 
ARR when compared to E. coli not expressing ARR. Neither culture showed any 
visible growth at 50 ºC. 
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4 Discussion 
4.1 Expression of ARR 
Satisfactory over-expression of ARR was not obtained using the pQE-30 plasmid. 
Purification of the protein was possible because of low levels of uninduced 
expression. Problems with expressing the protein in this vector have been reported 
previously (Puhaca, 2004) although in that work only E. coli MM2942 cells were 
used. Three cell lines were investigated in this work (E. coli MM2942; E. coli 
SG13009 (pREP) and E. coli (DE3) pLysS) to determine if the vector was the cause 
of a lack of over-expression. None of these cell lines produced favourable results, 
including the E. coli SG13009 (pREP) strain which is recommended by Qiagen for 
optimal expression. The choice of cell line used in over-expressing ARR from the 
pQE-30 vector can thus be excluded as a limiting factor. 
 
Arr has a GUG initiation codon and in mycobacteria this is not uncommon (Quan et 
al., 1997). However, in E. coli and other organisms the GUG initiation codon is not 
common. In eukaryotes translation is always initiated at an AUG codon however in 
bacteria there is slightly more flexibility and initiation can occur although rarely at 
GUG and even more infrequently at UUG (Ringquist et al., 1992) 
 
Changing a UUG or GUG to an AUG initiation codon has been shown to drastically 
increase levels of expression in E. coli (Reddy et al., 1985). In the above study it was 
even suggested that alternative initiation codons were used as a means to ensure low 
levels of expression. Not only is AUG the most efficient initiation codon in nearly all 
organisms but the level of transcription from an AUG start codon is also the least 
sensitive to the sequence of the second codon (O’Donnell and Janssen, 2000). 
 
However in the pQE-30 vector the 6xHis tag is expressed N-terminally or at the 5′-
end of the open reading frame and the vector thus uses its own start codon at the 
beginning of the tag sequence. This codon is an AUG initiation codon. Should the 
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ARR gene be cloned into another untagged or C-terminally tagged vector, the GUG 
codon may have to be taken into consideration. 
 
Other factors affecting the level of expression of heterologously expressed proteins in 
E. coli involve the 5′ untranslated region (UTR) of the gene’s mRNA. In other words, 
the vector sequence directly upstream of the initiation start site. The most important 
region of the UTR in terms of expression is the ribosomal binding site or Shine-
Delgarno site. This site must be accessible to the 30S ribosomal subunit in order for 
translation to take place. It has been shown previously that expression cannot take 
place when mRNA forms stable stem loop structures involving this site (Wood et al., 
1984). 
 
To investigate whether secondary mRNA structures play a role in the expression of 
ARR using the pQE-30 vector, the Mfold program (Zuker, 2003) was used to identify 
possible stem loop structures in the mRNA. A stem loop structure which included the 
Shine-Delgarno site was predicted (Figure 4.1). This structure has a predicted Tm of 
65 ºC. This means that the structure would be stable at a temperature of 37 ºC (the 
temperature at which the cells in this study were grown during expression).  
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Figure 4.1 Hypothetical secondary structure of arr mRNA when expressed using the 
pQE-30 vector as predicted by the Mfold software (Zuker, 2003). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
81 
 
This seems the most likely cause of low expression levels when attempting to express 
ARR using the pQE-30 vector. To overcome this problem, another vector which does 
not have any complimentarity with the 5′ end of the ARR gene should be used. This 
is in agreement with reports that ARR has been successfully overexpressed in the 
pET series of vectors (Gianniosis, 2007; Baysarowich et al., 2008). The hypothetical 
secondary structure of a pET ARR construct could be inspected for stem loop 
structures using the mFold program. This structure would be dependent on the choice 
of pET vector, as well as, which restriction sites are used within the pET vector. 
 
Further attempts to validate the identity of the protein purified in this work could 
have been made using a western blot specific for his-tagged proteins, however, there 
is reasonable certainty that the correct protein obtained was ARR because of size and 
spectrographic properties. 
 
4.2 Spectroscopic studies 
4.2.1 Far-UV CD 
The far-UV CD spectrum of native ARR shows two distinct minima, one at 210 nm 
and one at 222 nm. This spectrum is typical of proteins which contain both α-helices 
and β-strands The minimum, which occurs at 210 nm, is expected to be more 
negative in intensity than the minimum occurring at 222 nm in proteins of mixed 
secondary structure (Manavalan and Johnson, 1983). The far-UV CD spectrum of 
ARR is consistent with the crystal structure of ARR which shows ARR to be 18 % α-
helical and 29% β-stranded. 
 
Although the far-UV CD spectrum of ARR was predictable once the crystal structure 
of ARR had been solved (which occurred during the course of this work) and 
provided no novel information about the secondary structure of the protein, it may be 
useful as a reference point in NADP binding studies using far-UV CD as a probe 
similar to those done on dehydrogenase and NADH (for example Lange et al., 1974) 
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4.2.2 Thermal stability 
Both the thermal unfolding curve and the far-UV CD spectrum of ARR, once it had 
been heated to 95 ºC, show that ARR retains about 50% structure after heating, 
however once denatured ARR does not refold. These findings are consistent with 
previous reports that ARR maintains activity after heating (Quan et al. ,1997, 
Gianoissis, 2007). This indicates that the binding sites of NAD+ and rifampicin as 
well as the active site retain their structural integrity during heating. Due to its 
relatively high thermal stability and putative role in cell wall morphology 
investigations were done to determine whether ARR conferred any thermostability to 
the cells in which it is expressed. It was found that ARR had no influence on the 
cell’s ability to grow at higher temperatures. 
 
4.2.3 Intrinsic fluorescence 
The intrinsic fluorescence spectra of ARR correspond well to its crystal structure. 
ARR contains five tyrosine residues and two tryptophan residues. The tryptophan 
residues are solvent exposed. The intensity of the emission maximum is much higher 
with an excitation wavelength of 280 nm than 295 nm because at 280 nm both 
tyrosine and tryptophan residues are contributing to the emission wavelength, 
whereas, at 295 nm only tryptophan residues are contributing. 
 
The wavelength emission maximum of tryptophan is highly dependent on solvent 
accessibility. The emission maximum of free tryptophan in water is near 360 nm 
(Lakowicz, 1983). The more solvent exposed tryptophan residues are within a protein 
the closer the emission maximum will be to 360 nm. The emission maximum of    
350 nm of the tryptophans in ARR is consistent with two solvent exposed tryptophan 
residues. 
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4.2.4 Binding studies 
The red shift observed would be explained by an increase in the solvent accessibility 
of the tryptophan residues in ARR. This is contradictory to what was expected, as 
tryptophan 57 is buried when rifampicin binds to ARR, which would lead to blue 
shift. However, no conclusions can be drawn from this study because of the large 
inner filter effects caused by rifampicin’s absorbance at 295 nm. 
 
 
4.3 Changes in cell wall morphology 
Although there have been previous reports of cell wall changes to E. coli 
heterologously expressing ARR, this is the first report of cell morphology changes to 
M. smegmatis in the absence of ARR production. The only other known pathway in 
which ADP-ribosylation plays a role in cell morphology is the bld pathway in S. 
coelicolor. It appears that the ADP-ribosylation which occurs via ARR in M. 
smegmatis may be very similar to the ADP-ribosylation which takes place as part of 
the bld pathway in S. coelicolor. 
 
Three of the four proteins identified as ADP-ribosylation targets in the bld pathway 
(Sugawara et al.,2002) have homologues in M. smegmatis, identified using a BLAST 
alignment (Altschul et al., 1990) see Figure 4.2- 4.4. BldKB shows significant 
sequence identity with the M. smegmatis Extracellular Binding Protein, MalE shows 
significant sequence identity with the M. smegmatis Sugar Binding Protein and the 
Solute Binding Protein with the M. smegmatis D-xylose-binding periplasmic protein. 
The fourth target, a periplasmic protein required in binding branched-chain amino-
acids, appears to have no homologues in M. smegmatis. 
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Figure 4.2 BLAST alignment of S. coelicolor BldKB NP_629263.1| (Query) with M. 
smegmatis extracellular binding protein YP_888816.1 (Subject). Hypothetical ADP-
ribosylated cysteine is marked with an arrow. 
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Figure 4.3 BLAST alignment of S. coelicolor MalE NP_626482 (Query) with M. 
smegmatis sugar binding lipoprotein YP_884927.1 (Subject). Hypothetical ADP-
ribosylated cysteine is marked with an arrow. 
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Figure 4.4 BLAST alignment of S. coelicolor solute binding protein 
NP_630123.1 (Query) with M. smegmatis D-xylose-binding periplasmic protein 
YP_890244.1 (Subject). The probable ADP-ribosylated cysteine is marked with 
an arrow. 
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The cysteine residue in the four ADP-ribosylated proteins in S. coelicolor which 
is thought to be ADP-ribosylated (Sugawara et al.,2002) is conserved in the 
extracellular solute binding protein, the sugar binding protein and the extracellular 
binding protein (in M. smegmatis) making the same mechanism of ADP-
ribosylation possible in both species. A statistical study showed that it is highly 
probable that this cysteine is part of a signal sequence in the biosynthetic pathway 
which forms N-acyl-diacylglycerylcysteine a hallmark of bacterial lipoproteins 
(Sugawara et al., 2002). If the M. smegmatis extracellular solute binding protein 
is ADP-ribosylated it would not be able to be exported to the cell surface and 
assist in the transport of solutes across the cell membrane. 
 
Moreover, there may have been evolutionary pressure for M. smegmatis to keep 
the arr gene as it appears that the cell wall changes conferred by this gene may 
help bacteria endure stress. This conclusion can be drawn from the finding made 
by Mukherjee and Chatterji in 2005 that arr is down-regulated in the sigma B null 
mutant of M. smegmatis. 
 
Bacteria often have several alternative sigma factors of core RNA polymerase 
which enable them to differentially regulate large sets of genes (Review by 
Winkler and Breaker, 2005). Sigma factors are polypeptides which associate with 
the DNA-dependent RNA polymerase. The sigma factors are responsible for 
promoter recognition. Different sigma factors recognise different sets of 
promoters. In this way it is possible for large sets of genes to be regulated by the 
regulation of corresponding sigma factors. 
 
One of the most common needs for such large scale regulation is environmental 
factors, especially stress. In M. smegmatis, the major stress induced sigma factor 
is SigB (Manganelli et al., 1999). Genes which are regulated by sigB are 
generally considered to be stress related. Many of the proteins found to be up-
regulated by sigB are related to the cell wall (Mukherjee and Chatterji, 2005).  It 
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is interesting to note that there is also an alternative sigma factor (bldN) involved 
in the bld pathway in S. coelicolor (Bibb and Butter, 2000). 
 
Although the cells which showed cell wall morphology changes were not under 
typical stress conditions (unfavourable temperatures, high salt concentration), 
they were all in the stationary phase of growth which can lead to stress responses 
in cells due to high levels of metabolic waste in the media as well as a lack of 
nutrients (especially a carbohydrate source) and oxygen. A link between cell wall 
morphology and nutrient starvation in M. smegmatis has already been established 
(Ojha et al., 2000). Cells which are nutrient-starved are shorter than cells under 
normal growth conditions. 
 
There is evidence that lateral gene transfer between M. smegmatis and S. 
coelicolor is possible. They are both soil dwelling bacteria. S. coelicolor has a 
linear genome which has long been known to have a high level of genome 
instability (Chen et al.,2002) and Nocardia, evolutionarily closely related to S. 
coelicolor, and Mycobacterium, can conjugate with either species being the donor 
(Schupp et al.,1975). However, it does not seem likely that arr originated from S. 
coelicolor as at least three other proteins involved in the ADP-ribosylation which 
leads to changes in cell wall morphology in S. coelicolor are also present in M. 
smegmatis. 
 
The locus which was determined to be responsible for ADP-ribosylation of 
proteins during morphological differentiation in S. coelicolor was named bergA 
by Ochi and colleagues and a rough location on the genome was mapped. 
However, no sequence was elucidated for this gene. That work was concluded 
before the sequencing of the S. coelicolor genome was undertaken. Although the 
genome has been largely annotated it is unclear which sequenced gene 
corresponds to the bergA locus. It is possible that the ARR homologue, ARR2, is 
the product of the bergA locus. 
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It appears that M. smegmatis has a pathway involving ADP-ribosylation which is 
similar to the pathway which leads to aerial spore formation in S. coelicolor. In 
M. smegmatis, this pathway may be involved in stress response (possibly the 
physiological stress the cell experiences during the stationary phase of growth). It 
is unclear whether ADP-ribosylation of the putative targets of ARR (identified in 
this work) is responsible for the changes in cell wall morphology or whether they 
are involved in other, as yet, undiscovered aspects of this pathway. 
 
In order to determine whether M. smegmatis has a pathway similar to that of  the 
bld pathway of S. coelicolor, it would be necessary to evaluate the ADP-
ribosylation patterns of M. smegmatis with and without the production of ARR 
using the method of Sugawara et al., 2002. If the three M. smegmatis proteins 
identified as putative ARR targets in this work are differentially ADP-ribosylated, 
the role of the cysteine identified as a possible site of ADP-ribosylation could be 
determined using site-directed mutagenesis. It would also be interesting to 
determine whether ARR is involved in a stress response to stationary phase 
conditions by assessing mRNA levels during different growth phases by use of 
quantitative real-time PCR. 
 
If ARR is part of a stress response pathway, it is not clear how or when the 
protein acquired the ability to inactivate rifampicin. It does not appear that this 
function is present in S. coelicolor as there have been no reports of innate 
rifampicin resistance via ADP-ribosylation.  
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